BillionToOne
BillionToOne

BillionToOne, Inc (NASDAQ: BLLN), a leading molecular diagnostics company specializing in next-generation prenatal screening and oncology testing, saw its shares rise sharply in recent trading as investors responded to the firm's robust financial performance and upwardly revised growth outlook for 2026.

The stock closed at $69.11 on March 13, up $5.08 or 7.93% from the previous session, with trading volume reaching approximately 230,000 shares. In after-hours trading, the shares gained an additional $0.89. The gain followed a period of volatility, with the stock trading in a day's range of $64.03 to $69.11. BillionToOne's 52-week range spans from a low of $61.96 to a high of $138.70, achieved late last year shortly after its public debut.

The company, headquartered in Menlo Park, California, went public in November 2025 through an upsized initial public offering that priced at $60 per share. BillionToOne offered about 4.55 million shares of Class A common stock, raising gross proceeds of approximately $273.1 million before underwriters' options. The underwriters fully exercised their option for additional shares, boosting the total raised. Shares began trading on the Nasdaq Global Select Market under the ticker "BLLN" on Nov. 6, 2025, and opened significantly higher at around $100, reflecting strong initial demand and giving the company a market value exceeding $4 billion at that peak.

BillionToOne's core technology revolves around its proprietary quantitative counting platform, which enables highly accurate detection and quantification of DNA molecules in blood samples. This approach powers flagship products in prenatal diagnostics, such as non-invasive tests for fetal genetic conditions, and in oncology through liquid biopsy applications for cancer monitoring, including minimal residual disease (MRD) detection.

The firm's momentum stems from its latest earnings report released March 4, 2026. For the fourth quarter of 2025, BillionToOne reported revenue of $96.1 million, with a gross margin of 71%. Operating income reached $10.3 million, and net income stood at $4.4 million. For the full year 2025, total revenue doubled to $305.1 million from the prior year, marking a significant milestone as the company achieved profitability driven by increased testing volumes in both prenatal and oncology segments, along with higher average selling prices.

In the same release, management raised its full-year 2026 revenue guidance to a range of $430 million to $445 million, up from a previous forecast of $415 million to $430 million. This implies year-over-year growth of about 41% to 46% from the 2025 midpoint. The company also anticipates positive operating income for 2026, underscoring its path toward sustained profitability in a competitive diagnostics landscape.

"From breakthrough science to public company — BillionToOne now trades on NASDAQ under the symbol BLLN," the company highlighted on its website, emphasizing its transition from a venture-backed startup to a publicly traded entity.

Analysts have responded positively to the developments. The consensus rating remains a "Buy," with an average 12-month price target around $119.57, suggesting substantial upside potential of more than 70% from recent levels. Targets range from a low of $90 to a high of $145. Some observers point to the company's high price-to-sales ratio—around 15 based on trailing figures—and forward price-to-earnings multiple exceeding 280 as reflections of market expectations for rapid earnings expansion in precision medicine.

BillionToOne's growth strategy includes expanding its sales force and launching new applications on its Northstar platform, such as tumor-naive MRD tests expected by the end of 2026. The company has emphasized disciplined execution and accessibility in making advanced molecular tests widely available.

Despite the recent uptick, shares remain well below their post-IPO peak, trading at levels that some analysts view as undervalued relative to intrinsic estimates. One analysis suggested a narrative fair value above $135, indicating the stock could be overlooked amid broader sector fluctuations.

Founded in 2016 by Oguzhan Atay, Sukrit Silas and others, BillionToOne previously raised significant private funding, achieving unicorn status with a valuation over $1 billion in a 2024 Series D round. The IPO marked a key inflection point, providing capital for scaling operations and advancing its pipeline in liquid biopsy and prenatal care.

Investors continue to monitor the company's ability to maintain high growth rates while navigating reimbursement challenges common in diagnostics and competition from established players in oncology testing and prenatal screening.

As of mid-March 2026, BillionToOne's market capitalization hovers around $3.2 billion to $3.8 billion, depending on the latest close, positioning it as a notable player in the rapidly evolving precision diagnostics market.